Published in Clin Cancer Res on January 01, 2008
Macrophages and cathepsin proteases blunt chemotherapeutic response in breast cancer. Genes Dev (2011) 3.04
Anaplastic thyroid cancer: molecular pathogenesis and emerging therapies. Endocr Relat Cancer (2008) 2.10
Biobanking of human pancreas cancer tissue: impact of ex-vivo procurement times on RNA quality. Ann Surg Oncol (2010) 1.37
Metronomic chemotherapy: changing the paradigm that more is better. Curr Oncol (2009) 1.22
Metronomic gemcitabine in combination with sunitinib inhibits multisite metastasis and increases survival in an orthotopic model of pancreatic cancer. Mol Cancer Ther (2010) 1.07
Pleiotropic actions of miR-21 highlight the critical role of deregulated stromal microRNAs during colorectal cancer progression. Cell Death Dis (2013) 1.07
Recapitulation of pancreatic neuroendocrine tumors in human multiple endocrine neoplasia type I syndrome via Pdx1-directed inactivation of Men1. Cancer Res (2009) 1.05
Functional characterization of filamin a interacting protein 1-like, a novel candidate for antivascular cancer therapy. Cancer Res (2008) 1.04
Sunitinib inhibits lymphatic endothelial cell functions and lymph node metastasis in a breast cancer model through inhibition of vascular endothelial growth factor receptor 3. Breast Cancer Res (2011) 0.99
A digest on the role of the tumor microenvironment in gastrointestinal cancers. Cancer Microenviron (2010) 0.97
Clinical, pharmacokinetic and pharmacodynamic evaluations of metronomic UFT and cyclophosphamide plus celecoxib in patients with advanced refractory gastrointestinal cancers. Angiogenesis (2012) 0.96
PDGFRα up-regulation mediated by sonic hedgehog pathway activation leads to BRAF inhibitor resistance in melanoma cells with BRAF mutation. Oncotarget (2014) 0.94
A phase 1 trial of imatinib, bevacizumab, and metronomic cyclophosphamide in advanced colorectal cancer. Br J Cancer (2013) 0.94
Inhibition of metastatic potential in colorectal carcinoma in vivo and in vitro using immunomodulatory drugs (IMiDs). Br J Cancer (2009) 0.92
An in vitro study, evaluating the effect of sunitinib and/or lapatinib on two glioma cell lines. Invest New Drugs (2009) 0.87
Stratifying risk of recurrence in stage II colorectal cancer using deregulated stromal and epithelial microRNAs. Oncotarget (2015) 0.86
Synergistic inhibition of endothelial cell proliferation, tube formation, and sprouting by cyclosporin A and itraconazole. PLoS One (2011) 0.82
The differential effects of metronomic gemcitabine and antiangiogenic treatment in patient-derived xenografts of pancreatic cancer: treatment effects on metabolism, vascular function, cell proliferation, and tumor growth. Angiogenesis (2016) 0.79
Low-dosage metronomic chemotherapy and angiogenesis: topoisomerase inhibitors irinotecan and mitoxantrone stimulate VEGF-A-mediated angiogenesis. APMIS (2011) 0.78
A phase I study of sunitinib combined with modified FOLFOX6 in patients with advanced solid tumors. Cancer Chemother Pharmacol (2012) 0.78
The pancreatic niche inhibits the effectiveness of sunitinib treatment of pancreatic cancer. Oncotarget (2016) 0.75
Clinical Trials of Antiangiogenesis Therapy on Gastric Cancer. Gastroenterology Res (2008) 0.75
A multifunctional drug combination shows highly potent therapeutic efficacy against human cancer xenografts in athymic mice. PLoS One (2014) 0.75
Successful use of cyclophosphamide as an add-on therapy for multiple myeloma patients with acquired resistance to bortezomib or lenalidomide. Case Rep Hematol (2013) 0.75
A phase I/II study of lenalidomide in combination with sunitinib in patients with advanced or metastatic renal cell carcinoma. Ann Oncol (2014) 0.75
Silencing of TGF-β1 in tumor cells impacts MMP-9 in tumor microenvironment. Sci Rep (2017) 0.75
Extreme low dose of 5-fluorouracil reverses MDR in cancer by sensitizing cancer associated fibroblasts and down-regulating P-gp. PLoS One (2017) 0.75
Cancer regression in patients after transfer of genetically engineered lymphocytes. Science (2006) 16.96
Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol (2005) 12.88
Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4. J Clin Oncol (2005) 9.72
Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. Blood (2009) 9.24
Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4. J Clin Oncol (2006) 7.40
von Hippel-Lindau disease. Lancet (2003) 6.20
Prognostic factors related to clinical response in patients with metastatic melanoma treated by CTL-associated antigen-4 blockade. Clin Cancer Res (2007) 5.51
Tumor regression and autoimmunity in patients treated with cytotoxic T lymphocyte-associated antigen 4 blockade and interleukin 2: a phase I/II study. Ann Surg Oncol (2005) 5.36
Post-analysis follow-up and validation of microarray experiments. Nat Genet (2002) 4.61
Tumor progression can occur despite the induction of very high levels of self/tumor antigen-specific CD8+ T cells in patients with melanoma. J Immunol (2005) 3.73
Keynote review: phosphodiesterase-4 as a therapeutic target. Drug Discov Today (2005) 3.20
Cytotoxic T-lymphocyte-associated antigen-4 blockage can induce autoimmune hypophysitis in patients with metastatic melanoma and renal cancer. J Immunother (2005) 2.84
lenalidomide enhances natural killer cell and monocyte-mediated antibody-dependent cellular cytotoxicity of rituximab-treated CD20+ tumor cells. Clin Cancer Res (2008) 2.79
Randomized multicenter trial of hyperthermic isolated limb perfusion with melphalan alone compared with melphalan plus tumor necrosis factor: American College of Surgeons Oncology Group Trial Z0020. J Clin Oncol (2006) 2.60
MicroRNA dynamics in the stages of tumorigenesis correlate with hallmark capabilities of cancer. Genes Dev (2009) 2.41
The anti-cancer agents lenalidomide and pomalidomide inhibit the proliferation and function of T regulatory cells. Cancer Immunol Immunother (2008) 2.21
Prospective molecular profiling of melanoma metastases suggests classifiers of immune responsiveness. Cancer Res (2002) 2.21
Pulsed-high intensity focused ultrasound and low temperature-sensitive liposomes for enhanced targeted drug delivery and antitumor effect. Clin Cancer Res (2007) 2.17
Treatment of metastatic melanoma using interleukin-2 alone or in conjunction with vaccines. Clin Cancer Res (2008) 2.15
Somatic and germline CACNA1D calcium channel mutations in aldosterone-producing adenomas and primary aldosteronism. Nat Genet (2013) 2.09
Analysis of factors associated with outcome in patients with malignant peritoneal mesothelioma undergoing surgical debulking and intraperitoneal chemotherapy. J Clin Oncol (2003) 2.05
Gene expression profiles derived from fine needle aspiration correlate with response to systemic chemotherapy in breast cancer. Breast Cancer Res (2002) 2.04
Interleukin-1 and cancer progression: the emerging role of interleukin-1 receptor antagonist as a novel therapeutic agent in cancer treatment. J Transl Med (2006) 1.98
Molecular alterations in primary prostate cancer after androgen ablation therapy. Clin Cancer Res (2005) 1.88
Phase I and pharmacokinetic studies of CYT-6091, a novel PEGylated colloidal gold-rhTNF nanomedicine. Clin Cancer Res (2010) 1.87
Factors in tissue handling and processing that impact RNA obtained from formalin-fixed, paraffin-embedded tissue. J Histochem Cytochem (2008) 1.81
Gene promoter methylation in prostate tumor-associated stromal cells. J Natl Cancer Inst (2006) 1.70
Consequences of adrenal venous sampling in primary hyperaldosteronism and predictors of unilateral adrenal disease. J Am Coll Surg (2010) 1.70
The role of interleukin 1 in growth and metastasis of human cancer xenografts. Clin Cancer Res (2006) 1.68
Clinical, genetic and radiographic analysis of 108 patients with von Hippel-Lindau disease (VHL) manifested by pancreatic neuroendocrine neoplasms (PNETs). Surgery (2007) 1.67
Intrapatient dose escalation of anti-CTLA-4 antibody in patients with metastatic melanoma. J Immunother (2006) 1.66
Prospective analysis of circulating endostatin levels in patients with renal cell carcinoma. Cancer (2002) 1.65
Localization of insulinomas to regions of the pancreas by intraarterial calcium stimulation: the NIH experience. J Clin Endocrinol Metab (2009) 1.62
A 90-day oral gavage toxicity study of D-methylphenidate and D,L-methylphenidate in Sprague-Dawley rats. Toxicology (2002) 1.62
Effects of acute insulin-induced hypoglycemia on indices of inflammation: putative mechanism for aggravating vascular disease in diabetes. Diabetes Care (2010) 1.57
Interleukin-4 cytotoxin therapy synergizes with gemcitabine in a mouse model of pancreatic ductal adenocarcinoma. Cancer Res (2007) 1.55
Regional treatment options for patients with ocular melanoma metastatic to the liver. Ann Surg Oncol (2004) 1.55
Orally administered lenalidomide (CC-5013) is anti-angiogenic in vivo and inhibits endothelial cell migration and Akt phosphorylation in vitro. Microvasc Res (2005) 1.52
Tobacco smoke induces polycomb-mediated repression of Dickkopf-1 in lung cancer cells. Cancer Res (2009) 1.50
Pomalidomide and lenalidomide regulate erythropoiesis and fetal hemoglobin production in human CD34+ cells. J Clin Invest (2008) 1.50
Reoperation for parathyroid adenoma: a contemporary experience. Surgery (2009) 1.50
Partial-volume correction in PET: validation of an iterative postreconstruction method with phantom and patient data. J Nucl Med (2007) 1.49
Gold nanoparticles for the improved anticancer drug delivery of the active component of oxaliplatin. J Am Chem Soc (2010) 1.47
Thalidomide metabolites in mice and patients with multiple myeloma. Clin Cancer Res (2003) 1.43
Direct evidence for rapid and selective induction of tumor neovascular permeability by tumor necrosis factor and a novel derivative, colloidal gold bound tumor necrosis factor. Int J Cancer (2007) 1.43
IMiD immunomodulatory compounds block C/EBP{beta} translation through eIF4E down-regulation resulting in inhibition of MM. Blood (2011) 1.43
Comparison of noninvasive fluorescent and bioluminescent small animal optical imaging. Biotechniques (2003) 1.36
Radiofrequency ablation of adrenal tumors and adrenocortical carcinoma metastases. Cancer (2003) 1.36
Thalidomide and lenalidomide extend survival in a transgenic mouse model of amyotrophic lateral sclerosis. J Neurosci (2006) 1.34
Launching a novel preclinical infrastructure: comparative oncology trials consortium directed therapeutic targeting of TNFalpha to cancer vasculature. PLoS One (2009) 1.33
Integration of metabolomics and transcriptomics revealed a fatty acid network exerting growth inhibitory effects in human pancreatic cancer. Clin Cancer Res (2013) 1.31
Parathyroid-specific double knockout of Gq and G11 alpha-subunits leads to a phenotype resembling germline knockout of the extracellular Ca2+ -sensing receptor. Mol Endocrinol (2006) 1.31
Comparison of SUV and Patlak slope for monitoring of cancer therapy using serial PET scans. Eur J Nucl Med Mol Imaging (2002) 1.30
A short history of the polymerase chain reaction. Methods Mol Biol (2003) 1.30
Current advances in molecular imaging: noninvasive in vivo bioluminescent and fluorescent optical imaging in cancer research. Mol Imaging (2003) 1.30
DPEP1 inhibits tumor cell invasiveness, enhances chemosensitivity and predicts clinical outcome in pancreatic ductal adenocarcinoma. PLoS One (2012) 1.30
Phosphodiesterase-4 inhibition alters gene expression and improves isoniazid-mediated clearance of Mycobacterium tuberculosis in rabbit lungs. PLoS Pathog (2011) 1.29
Determination of the elimination half-life of fibroblast growth factor-23. J Clin Endocrinol Metab (2007) 1.27
Successful outcome after surgical management in two cases of the "painful variant" of Hashimoto's thyroiditis. Endocr Pract (2002) 1.25
Tumor vasculature-targeted delivery of tumor necrosis factor-alpha. Cancer (2009) 1.25
SIVQ-aided laser capture microdissection: A tool for high-throughput expression profiling. J Pathol Inform (2011) 1.24
Parathyroid gland-specific deletion of the mouse Men1 gene results in parathyroid neoplasia and hypercalcemic hyperparathyroidism. Cancer Res (2003) 1.22
Gene array analysis of macronodular adrenal hyperplasia confirms clinical heterogeneity and identifies several candidate genes as molecular mediators. Oncogene (2004) 1.22
Using gene expression profiling to differentiate benign versus malignant thyroid tumors. Cancer Res (2004) 1.21
Development of a clinical decision model for thyroid nodules. BMC Surg (2009) 1.21
Oncolytic vaccinia virus expressing the human somatostatin receptor SSTR2: molecular imaging after systemic delivery using 111In-pentetreotide. Mol Ther (2004) 1.21
Insulinoma: pathophysiology, localization and management. Future Oncol (2010) 1.21
Recognition of NY-ESO-1+ tumor cells by engineered lymphocytes is enhanced by improved vector design and epigenetic modulation of tumor antigen expression. Cancer Immunol Immunother (2008) 1.21
Does the use of routine duodenotomy (DUODX) affect rate of cure, development of liver metastases, or survival in patients with Zollinger-Ellison syndrome? Ann Surg (2004) 1.20
Possible primary lymph node gastrinoma: occurrence, natural history, and predictive factors: a prospective study. Ann Surg (2003) 1.20
Phosphodiesterase 4 inhibition reduces innate immunity and improves isoniazid clearance of Mycobacterium tuberculosis in the lungs of infected mice. PLoS One (2011) 1.20
Neighborhood mapping and evaluation: a methodology for participatory community health initiatives. Matern Child Health J (2007) 1.19
Phosphodiesterase-4 inhibition combined with isoniazid treatment of rabbits with pulmonary tuberculosis reduces macrophage activation and lung pathology. Am J Pathol (2011) 1.19
A pilot feasibility study of TNFerade™ biologic with capecitabine and radiation therapy followed by surgical resection for the treatment of rectal cancer. Oncology (2011) 1.18